Related Experiment Video
Updated: Oct 25, 2025

Skeletal Phenotype Analysis of a Conditional Stat3 Deletion Mouse Model
Published on: July 3, 2020
Long-Term Effects of Sglt2 Deletion on Bone and Mineral Metabolism in Mice
Claire Gerber1,2, Xueyan Wang1,2,3, Valentin David1,2,3
1Division of Nephrology and Hypertension, Feinberg School of Medicine Northwestern University Chicago IL USA.
Abstract:
Sodium-glucose cotransporter 2 (SGLT2) inhibitors improve kidney and cardiovascular outcomes in patients with type 2 diabetes mellitus (T2DM). However, bone fragility has emerged as a side effect in some but not in all human studies. Because use of SGLT2 inhibitors in humans affects mineral metabolism, we investigated the long-term effects of genetic loss of Sglt2 function on bone and mineral metabolism in mice. Slc5a2 nonsense mutation in Sweet Pee (SP) mice results in total loss of Sglt2 function. We collected urine, serum, and bone samples from 15-week-old and 25-week-old wild-type (WT) and SP mice fasted from food overnight. We measured parameters of renal function and mineral metabolism and we assessed bone growth, microarchitecture, and mineralization. As expected, 15-week-old and 25-week-old SP mice showed increased glucosuria, and normal kidney function compared to age-matched WT mice. At 15 weeks, SP mice did not show alterations in mineral metabolism parameters. At 25 weeks, SP mice showed reduced fasting 24-hour urinary calcium excretion and increased fractional excretion of phosphate, but normal serum calcium and phosphate, parathyroid hormone (PTH), vitamin D (1,25(OH)2D), and fibroblast growth factor (FGF23) levels. At 25 weeks, but not at 15 weeks, SP mice showed reduced body weight compared to WT. This was associated with reduced femur length at 25 weeks, suggesting impaired skeletal growth. SP mice did not show trabecular or cortical bone microarchitectural modifications but showed reduced cortical bone mineral density compared to WT mice at 25 weeks. These results suggest that loss of Sglt2 function in mice in the absence of T2DM does not alter regulatory hormones FGF23, PTH, and 1,25(OH)2D, but may contribute to bone fragility over the long term. Future studies are required to determine how loss of Sglt2 function impacts bone fragility in T2DM. © 2021 The Authors. JBMR Plus published by Wiley Periodicals LLC on behalf of American Society for Bone and Mineral Research.
Insights
Genetic loss of sodium-glucose cotransporter 2 (SGLT2) function in mice impaired skeletal growth and reduced bone mineral density over time. This suggests SGLT2 inhibition may contribute to long-term bone fragility, even without type 2 diabetes mellitus.
Area of Science:
- Bone and Mineral Metabolism
- Endocrinology
- Nephrology
Background:
- Sodium-glucose cotransporter 2 (SGLT2) inhibitors benefit kidney and cardiovascular outcomes in type 2 diabetes mellitus (T2DM).
- Bone fragility is a potential side effect of SGLT2 inhibitors, possibly linked to altered mineral metabolism.
Purpose of the Study:
- To investigate the long-term effects of genetic SGLT2 loss on bone and mineral metabolism in mice.
- To determine if SGLT2 deficiency impacts skeletal growth, microarchitecture, and mineralization independently of T2DM.
Main Methods:
- Utilized Sweet Pee (SP) mice with a nonsense mutation in Slc5a2, leading to complete SGLT2 loss.
- Collected urine, serum, and bone samples from 15- and 25-week-old wild-type (WT) and SP mice.
- Assessed renal function, mineral metabolism, bone growth, microarchitecture, and mineralization.
Main Results:
- SP mice exhibited glucosuria but maintained normal kidney function.
- At 25 weeks, SP mice showed reduced urinary calcium excretion, increased fractional phosphate excretion, reduced body weight, and impaired femur length.
- Cortical bone mineral density was reduced in 25-week-old SP mice, without changes in bone microarchitecture or key regulatory hormones (FGF23, PTH, 1,25(OH)2D).
Conclusions:
- Long-term genetic loss of SGLT2 function in mice, in the absence of T2DM, is associated with impaired skeletal growth and reduced bone mineral density.
- These findings suggest a potential mechanism by which SGLT2 inhibition could contribute to bone fragility.
- Further research is needed to elucidate the impact of SGLT2 loss on bone fragility specifically in the context of T2DM.
More Related Videos
06:16Preparation Of Gushukang GSK Granules for In Vivo and In Vitro Experiments
Published on: May 9, 2019
04:24Proper Positioning and Restraint of a Rat Hind Limb for Focused High Resolution Imaging of Bone Micro-architecture Using In Vivo Micro-computed Tomography
Published on: November 22, 2017